C4 Therapeutics Reports Third-Quarter 2026 Results and Trial Update
The company said enrollment in its Phase 2 MOMENTUM trial of cemsidomide remains on track to finish in the first quarter of 2027, with initial ORR data expected.
Related stories
Tripadvisor Reports Third-Quarter Loss of $2.66 per Share
M impact | EQUITY | Nov 05, 2026, 12:22 PM UTC
DTE Energy reports third-quarter earnings
DTE Energy reported third-quarter earnings of $4.
M impact | EQUITY | Nov 05, 2026, 12:07 PM UTC
Appian Q3 Cloud Subscriptions Revenue Rises 20% to $136.4M
Appian reported Q3 2026 cloud subscriptions revenue of $136.4 million, up 20% year over year.
M impact | EQUITY | Nov 05, 2026, 12:07 PM UTC
Tripadvisor Reports Third-Quarter Revenue of $436.4 Million
Tripadvisor reported third-quarter revenue of $436.4 million.
M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC
Borussia Dortmund Q1 Net Profit Falls to €11.9M
Q1 revenue was €107.4M versus €107.0M a year earlier, while net profit fell to €11.9M from €22.9M. The company maintained its 2026/2027 net profit forecast of €0M to €10M.
M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC
Asian Tech Stocks Tumble in Tokyo and Seoul; Hong Kong Surges
South Korea’s KOSPI fell 5.3%, while Japan’s Nikkei 225 also declined. Hong Kong shares rose.
M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC